Background
Randomized Phase III trial (NCI) comparing aggressive combined-modality therapy vs. sequential topical therapy for advanced mycosis fungoides (MF). 103 patients with advanced-stage MF. Key question: does upfront aggressive treatment improve survival vs. conservative sequential approach?
Interventions and follow up
Arm A: Total skin electron beam therapy (TSEBT) 30 Gy followed by combination systemic chemotherapy (mechlorethamine, vincristine, procarbazine, prednisone — MOPP)
Arm B: Sequential topical therapy (topical HN2 or BCNU); systemic chemotherapy deferred until progressio
Primary endpoint: Overall survival, complete response rate
mFollow up: Median 75 month
Arm B: Sequential topical therapy (topical HN2 or BCNU); systemic chemotherapy deferred until progressio
Primary endpoint: Overall survival, complete response rate
mFollow up: Median 75 month
Results
CR rate: Arm A 38% vs. Arm B 18%, P=.032 (higher CR with aggressive therapy)
5-Year OS: 38% vs. 39% — no significant difference
DFS: No significant improvement in disease-free survival with aggressive therapy
Response duration: Not significantly prolonged in Arm A
5-Year OS: 38% vs. 39% — no significant difference
DFS: No significant improvement in disease-free survival with aggressive therapy
Response duration: Not significantly prolonged in Arm A
Adverse events
Main adverse events: Arm A: myelosuppression, alopecia, mucositis from chemotherapy; TSEBT-related skin toxicity (desquamation), nail changes, leg edema. Arm B: local skin toxicity from HN2/BCNU. Grade ≥3 systemic toxicity substantially higher in Arm A.
Conclusions
Despite a higher complete response rate with aggressive combined-modality therapy, there was no improvement in overall survival compared to sequential topical therapy. This landmark negative trial established that early aggressive treatment does not benefit patients with advanced MF and supports a conservative, sequential approach to management.
Key Limitations
Key Limitations: Small sample size (n=103); broad inclusion of advanced-stage MF with heterogeneous presentations; outdated chemotherapy regimen (MOPP); modern systemic agents (brentuximab, mogamulizumab, romidepsin) not available; RT technique less sophisticated than modern TSEBT.
Clinical Context
This NCI trial fundamentally shaped the treatment paradigm for MF: "treat to control symptoms, not to cure." Its finding that aggressive treatment does not improve OS supports the current standard of sequential therapy escalation. TSEBT remains reserved for patients with thick plaques or tumor-stage disease rather than upfront aggressive combination therapy.
References